Junmeng Biosciences Co., Ltd.

Intel Corporation

Shanghai Junshi Biosciences Co., Ltd.

Suzhou Junmeng Biosciences Co., Ltd.

Shanghai Junshi Biosciences Inc.

Basf Se Corporation

Junshi Biosciences Co., Ltd.

Hai Wu

Hui Feng

Jian Yao

Sheng Yao

Kai Chen

Dan Meng

Cheng Yang

Yuehua Zhou

Jiamin Qian

Jing Jing Zhang

Premanand Sakarda

Sunitha Grandhee

Jing Zhang

Rajesh Kumar

Nikolay Lebedinski

Libo Zhang

Hongchuan Liu

Todd Brandt

The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.

Anti-IL-17A antibody and use thereof

The present invention relates to an anti-BTLA antibody or an antigen-binding fragment thereof comprising: at least one light chain CDR domain selected from SEQ ID NOs: 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, 24, 31, 32 and 33, and/or at least one heavy chain CDR domain selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 13, 14, 15, 19, 20, 21, 25, 26, 27, 28, 29 and 30. The present invention also relates to a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a corresponding expression vector and a host cell, as well as therapeutic use of the antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the expression vector and the host cell.

Anti-BTLA antibody

An antibody or a functional fragment thereof that specifically bind to PD-L1 with high affinity, a nucleic acid molecule that encodes said antibody or the functional fragment thereof, an expression vector and a host cell for use in expressing said antibody or the functional fragment thereof, and a method for producing said antibody or the functional fragment thereof. An immunoconjugate and a pharmaceutical composition containing said antibody or the functional fragment thereof, and a method for using said antibody or the functional fragment thereof to enhance the function of a T cell so as to up-regulate a cell-mediated immune response, for use in treating diseases caused by T cell dysfunction.

Anti-PD-L1 antibody and application thereof

The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.

Anti-PCSK9 antibody and use thereof

This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.

Anti-PD-1 antibody and use thereof

This disclosure provides a solvent-borne system for forming an n-acyl urea coating on a substrate. In one embodiment, the solvent-borne system comprises a polycarbodiimide-polyurethane hybrid. The solvent-borne system also comprises an acid functional polymer and an organic solvent, and comprises less than or equal to 10 weight percent of water based on a total weight of said solvent-borne system. The solvent-borne system also comprises less than about 100 parts by weight of toluene diisocyanate per one million parts by weight of the solvent-borne system.

Solvent-borne system for forming an n-acyl urea coating

The present disclosure relates to forming a plurality of through silicon vias guard rings proximate the scribes streets of a microelectronic device wafer. The microelectronic device wafer includes a substrate wherein the through silicon via guard ring is fabricated by forming vias extending completely through the substrate. The through silicon via guard rings act as crack arresters, such that defects caused by cracks resulting from the dicing of the microelectronic wafer are substantially reduced or eliminated.

Through silicon via guard ring

Embodiments of a method and system for heterogeneous memory control are disclosed. The embodiments include components of a Memory Manager that receive usage information of a memory subsystem of a host system, the memory subsystem including internal memory and external memory. The Memory Manager also receives client information of one or more clients that are coupled to and/or integrated with the host system. A request or call for internal memory is also received at the Memory Manager from the clients. The Memory manager automatically controls the memory in accordance with one or more of the request, the usage information and the client information. The control includes allocating a portion of the internal memory to the client, remapping one or more areas of internal memory from a first client to a second client, and/or reorganizing the memory by remapping external memory to internal memory. Other embodiments are described and claimed.

Memory manager for heterogeneous memory control

Growing community of inventors

Shanghai, China

Hai Wu